Expanding the armamentarium for the treatment of Clostridium difficile infection

Affiliations

¹ Centre for Clinical Infection and Diagnostics Research, King's College London, and Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK. Electronic address: simon.goldenberg@gstt.nhs.uk.

Free article

Comment

Simon D Goldenberg. Lancet Infect Dis. 2017 Jul.

Free article

. 2017 Jul;17(7):678-680.

doi: 10.1016/S1473-3099(17)30237-2. Epub 2017 Apr 28.

¹ Centre for Clinical Infection and Diagnostics Research, King's College London, and Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK. Electronic address: simon.goldenberg@gstt.nhs.uk.

No abstract available

Comment on

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group. Vickers RJ, et al. Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28. Lancet Infect Dis. 2017. PMID: 28461207 Free PMC article. Clinical Trial.